Antibodies to β2‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Takao Koike, Masaya Mukai, Eiji Matsuura, Kenji Ichikawa, Akito Tsutsumi, Atsushi Fujisaku, Seiichi Kobayashi
1996-09-01

OBJECTIVE: To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to beta 2-glycoprotein I (beta 2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-beta 2GPI antibody and clinical manifestations in SLE patients. METHODS: IgG and IgM anti-beta 2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. RESULTS: The values of anti-beta 2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-beta 2GPI assay was more useful in distinguishing beta 2GPI-dependent aCL from beta 2GPI-independent aCL. The presence of IgG anti-beta 2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-beta 2GPI may fluctuate with disease activity. CONCLUSION: The results suggest that pathogenic aCL is directed against structurally altered beta 2GPI and that enzyme immunoassay for anti-beta 2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.
Publication Details
Publication Date
1996-09-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Takao Koike
Masaya Mukai
Eiji Matsuura
Kenji Ichikawa
Akito Tsutsumi
Atsushi Fujisaku
Seiichi Kobayashi
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%